Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larazotide for Persistent Symptoms in Celiac Disease
NCT03569007Phase 3Terminated
- Sponsor
- Innovate Biopharmaceuticals
- Start
- May 2019
- Primary completion
- Jul 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of larazotide in celiac disease, sponsored by Innovate Biopharmaceuticals. Started May 2019; status: terminated.
02
Drugs
larazotide
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT03569007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03569007.